secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047832
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute Q3 net loss $18.9M; sunRIZE enrollment on track, BTD for ersodetug
---------------------------------------------------------------------------

- Cash $88.4M at March 31, 2025, down from $127.1M at June 30, 2024.
- Phase 3 sunRIZE study enrollment expected to complete May 2025; topline results anticipated December 2025.
- FDA granted Breakthrough Therapy Designation to ersodetug for tumor hyperinsulinism hypoglycemia in May 2025.
- April 2025 underwritten offering raised ~$97M, extending cash runway to mid-2027.
- Appointed Erik Harris (Ultragenyx CCO) to Board of Directors in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/0001104659-25-047832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/tm2514822d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer